Processa Pharmaceuticals Stock Today
| PCSA Stock | USD 2.44 0.19 7.22% |
PerformanceWeakest
| Odds Of DistressSmall
|
Processa Pharmaceuticals is trading at 2.44 as of the 3rd of February 2026, a 7.22 percent decrease since the beginning of the trading day. The stock's open price was 2.63. Processa Pharmaceuticals has about a 34 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 5th of November 2025 and ending today, the 3rd of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of October 2017 | Category Healthcare | Classification Health Care |
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. The company was incorporated in 2011 and is based in Hanover, Maryland. The company has 2.27 M outstanding shares of which 30.09 K shares are at this time shorted by private and institutional investors with about 0.01 trading days to cover. More on Processa Pharmaceuticals
Moving together with Processa Stock
| 0.62 | VIVS | VivoSim Labs Symbol Change | PairCorr |
| 0.86 | EDIT | Editas Medicine | PairCorr |
| 0.95 | ENSC | Ensysce Biosciences | PairCorr |
Moving against Processa Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Processa Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsProcessa Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Processa Pharmaceuticals' financial leverage. It provides some insight into what part of Processa Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Processa Pharmaceuticals (PCSA) is traded on NASDAQ Exchange in USA and employs 10 people. Processa Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.8 M. Processa Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.27 M outstanding shares of which 30.09 K shares are at this time shorted by private and institutional investors with about 0.01 trading days to cover.
Processa Pharmaceuticals currently holds about 12.06 M in cash with (11.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76.
Check Processa Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationProcessa Pharmaceuticals holds 10.73 pct. of its outstanding shares held by insiders and 8.9 pct. owned by third-party entities.
Check Processa Ownership Details
Processa Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Sbi Securities Co Ltd | 2025-06-30 | 12.0 | |
| Advisor Group Holdings, Inc. | 2025-06-30 | 2.0 | |
| Miracle Mile Advisors, Inc. | 2025-06-30 | 0.0 | |
| Armistice Capital, Llc | 2025-06-30 | 0.0 | |
| Hrt Financial Llc | 2025-03-31 | 0.0 | |
| Virtu Financial Llc | 2025-06-30 | 104.7 K | |
| Ubs Group Ag | 2025-06-30 | 64.6 K | |
| Alpine Partners Vi, Llc | 2025-06-30 | 53.4 K | |
| Geode Capital Management, Llc | 2025-06-30 | 50.6 K | |
| Cubist Systematic Strategies, Llc | 2025-06-30 | 41.8 K | |
| Vanguard Group Inc | 2025-06-30 | 24.4 K |
Processa Pharmaceuticals Historical Income Statement
Processa Stock Against Markets
Processa Pharmaceuticals Corporate Management
| James Stanker | Chief Officer | Profile | |
| PharmD Bigora | CoFounder Officer | Profile | |
| Russell MBA | Chief Officer | Profile | |
| Steven MD | Senior Research | Profile | |
| Robert Floyd | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. Anticipated expansion of Processa directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Processa Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Processa Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Processa Pharmaceuticals' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Processa Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Processa Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Processa Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Processa Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.